Resources from the same session
LBA1 - Multicenter phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab (KCSG HB23-04)
Presenter: Changhoon Yoo
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
126O - Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW Asian subgroup analysis
Presenter: Thomas Yau
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
127O - Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Presenter: Masatoshi Kudo
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA1, 126O and 127O
Presenter: Joon Oh Park
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Slides
Webcast
Q&A and discussion
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Webcast
133O - Safety of 30 min infusion of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in first-line treatment (tx) of advanced biliary tract cancer (aBTC): TOURMALINE early results
Presenter: Masafumi Ikeda
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
134O - Asia subgroup overall survival and long-term follow-up results of the phase IIb HERIZON-BTC-01 study: Zanidatamab in previously treated human epidermal growth factor receptor 2 (HER2)-amplified biliary tract cancer (BTC)
Presenter: Jin Won Kim
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Webcast